$ENVB News

Last published 3w ago

3w agoENVBEnveric Biosciences Announces Positive Results from Recently Completed IND-enabling ADMET StudiesBusiness WireCompleted IND-enabling in vitro Absorption, Distribution, Metabolism, Excretion and Toxicity (ADMET) studies, demonstrating favorable and efficient oral absorption and systemic bioavailability Results further derisk
1mo agoENVBEnveric Biosciences Secures New U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 SeriesBusiness WireAllowed claims are expected to cover novel methylone-inspired neuroplastogenic compounds for potential treatment of post-traumatic stress disorder (PTSD) and other psychiatric disorders Enveric Biosciences
2mo agoENVBEnveric Biosciences to Present at H.C. Wainwright 28th Annual Global Investment ConferenceBusiness WireEnveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders,
2mo agoENVBEnveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026Business WireEB-003 Development Highlights: Continued advancing IND-enabling studies supporting the planned submission of an Investigational New Drug (IND) application for EB-003 and expected initiation of Phase 1 clinical
3mo agoENVBEnveric Biosciences Reports New Preclinical Data Supporting the Non-Hallucinogenic Profile of Lead Candidate EB-003Business WireGloSensor™ assay findings align with previously reported BRET assay data as EB-003 advances toward planned Phase 1 clinical development Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"),
3mo agoENVBEnveric Biosciences Welcomes Final FDA Guidance for Psychedelic Drug DevelopmentBusiness WireFDA guidance highlights clinical and delivery challenges associated with hallucinogenic compounds, supporting the potential advantages of Enveric’s EB-003 approach Enveric Biosciences (NASDAQ:ENVB) ("Enveric"
4mo agoENVBEnveric Biosciences Announces Participation in B. Riley Securities Mind, Muscle & Vision SummitBusiness WireEnveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders,
4mo agoENVBEnveric Biosciences Announces Participation in 2026 BIO International ConventionBusiness WireEnveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced
5mo agoENVBEnveric Biosciences to Participate in the UBS 3rd Virtual CNS DayBusiness WireEnveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced
5mo agoENVBEnveric Biosciences Initiates Investigational New Drug (IND)-enabling Genotoxicity Studies of Lead Neuroplastogen Candidate EB-003Business WireStudies are designed to evaluate the potential for the compound to interact with DNA and cause genetic mutations, a critical measure of safety required for IND submission Enveric Biosciences (NASDAQ:ENVB) ("Enveric"
5mo agoENVBEnveric Biosciences Reports Positive Preclinical Results from Phototoxicity Analysis for Lead Neuroplastogen Candidate EB-003Business WireAnalysis showed no photoreactive potential for EB-003, further derisking its continued development for the treatment of neuropsychiatric disorders including depression, anxiety and PTSD. Phototoxicity testing is a
6mo agoENVBEnveric Biosciences Reports Financial Results and Provides Corporate Update for First Quarter 2026Business WireProduct Development Highlights: Continued advancement of lead candidate EB-003 with IND-enabling studies progressing toward planned first-in-human clinical trial Reported additional preclinical data for EB-003
6mo agoENVBEnveric Biosciences Expands IP Portfolio with New U.S. Patent Issued for Methods of Treating Psychiatric DisordersBusiness WireClaims to methods for treating a psychiatric disorder using novel pharmaceutical drug formulations encompass an EVM301 Series of drug candidates of carboxylated psilocybin derivatives, targeting various
6mo agoENVBEnveric Biosciences Highlights Positive Results for EB-003 in PTSD Preclinical ModelBusiness WirePreviously reported results support continued development of EB-003 for PTSD and other neuropsychiatric conditions Recent U.S. Executive Order supporting psychedelic-inspired therapies highlights growing focus on PTSD
6mo agoLABT ENVBLakewood-Amedex Biotherapeutics Appoints Joseph Tucker, Ph.D., to Board of DirectorsPR NewswireLakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting,...
6mo agoENVBEnveric Biosciences to Participate in a Panel Discussion at Needham's Virtual Psychedelics ForumBusiness WireEnveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced
6mo agoENVBEnveric Biosciences Announces Closing of Up To $13.9 Million Private Placement Priced At-The-Market Under Nasdaq RulesBusiness Wire$5 million upfront with up to approximately $8.9 million of potential aggregate proceeds upon the exercise in full of warrants Enveric Biosciences, Inc. (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology
6mo agoENVBEnveric Biosciences Announces Up To $13.9 Million Private Placement Priced At-The-Market Under Nasdaq RulesBusiness Wire$5 million upfront with up to approximately $8.9 million of potential aggregate proceeds upon the exercise in full of warrants Enveric Biosciences, Inc. (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology
7mo agoENVBEnveric Biosciences Secures New U.S. Patent for Its EVM301 Series of Drug CandidatesBusiness WirePatent provides added depth to Enveric's EVM301 intellectual property portfolio of potential neuroplastogenic molecules for non-hallucinogenic treatment of neuropsychiatric conditions Enveric Biosciences (NASDAQ:ENVB)
7mo agoENVBEnveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2025Business WireProduct Development Highlights: Reported positive preclinical results for lead drug candidate EB-003, showing statistically significant improvements in animal models of severe chronic depression and despair and in
7mo agoENVBEnveric Biosciences Announces Registration of Five TrademarksBusiness WireCanadian Trademark Office Issues House Marks to Enveric Biosciences, Inc. Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule
8mo agoENVBEnveric Biosciences Announces Withdrawal of Petition Against Its PatentBusiness WireAs a result of this action, there are no remaining challenges currently pending against Enveric's patent Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel
8mo agoENVBEnveric Biosciences Reports EB-003 BRET Receptor Engagement Assay DataBusiness WireProprietary assays demonstrate dual Gq and β-arrestin signaling at 5-HT₂A, pathways linked in peer-reviewed studies to antidepressant and anxiolytic effects A recent independent Nature study reports that distinct
9mo agoENVBEnveric Biosciences Expands Collaboration with TOTEC Pharma through Trademark License and OptionBusiness WireRCANN™ Trademark Portfolio Out-Licensed Enveric Biosciences, Inc. (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address
9mo agoENVBEnveric Biosciences Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesBusiness WireEnveric Biosciences, Inc. (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced
10mo agoENVBEnveric Biosciences Announces Patent IssuanceBusiness WireU.S. Patent expands the scope of patent protection and increases the number of molecules that Enveric has the potential to develop or license for the treatment of neuropsychiatric conditions. Enveric Biosciences
11mo agoENVB FEEDENvue Medical Appoints Veteran Healthcare-Industry Executive, David Johnson, as ChairmanBusiness WireENvue Medical, Inc. (NASDAQ:FEED) ("ENvue" or the "Company"), a medical technology company specializing in non-invasive therapeutic systems, today announced the appointment of David Johnson as Chairman of the Board. Mr.
11mo agoENVBEnveric Biosciences Announces Closing of Exercise of Warrants for $3.1 Million Gross ProceedsBusiness WireEnveric Biosciences, Inc. (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced
11mo agoENVBEnveric Biosciences Announces Exercise of Warrants for $3.1 Million Gross ProceedsBusiness WireEnveric Biosciences, Inc. (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced
11mo agoENVBEnveric Biosciences Receives Notice of Allowance for EVM301 Series of Drug CandidatesBusiness WireOnce issued, this new U.S. Patent will expand the scope of Enveric's EVM301 patent portfolio of potential neuroplastogenic molecules for treatment of neuropsychiatric conditions. Enveric Biosciences (NASDAQ:ENVB)
11mo agoENVBEnveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 9th Annual Neuroscience Innovation Forum During "J.P. Morgan Week 2026"Business WireManagement to meet with investors and potential partners during Biotech Showcase 2026 Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic
11mo agoENVBEnveric Biosciences Receives Fourth Notice of Allowance for EVM401 Series of Drug CandidatesBusiness WireOnce issued, this new U.S. Patent will expand the scope of Enveric's EVM401 patent portfolio of potential neuroplastogenic molecules for non-hallucinogenic treatment of neuropsychiatric conditions. Enveric Biosciences
12mo agoENVBEnveric Biosciences Reports Third Quarter 2025 Financial and Corporate ResultsBusiness WireIn Q3, Enveric continued toward clinical readiness for lead candidate EB-003, targeting neuropsychiatric indications, announcing additional positive data in a preclinical model of PTSD, successful completion of dose
1y agoENVBEnveric Biosciences Announces Reverse Stock SplitBusiness WireCommon Stock Will Begin Trading on a Split-Adjusted Basis on October 28, 2025 Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small
1y agoENVBEnveric Biosciences Further Enhances Intellectual Property Estate with New U.S. Patent IssuanceBusiness WireNew patent marks Enveric's 23rd issued U.S. patent for novel neuroplastogen molecules, increasing Enveric's intellectual property footprint and supporting the potential for pipeline expansion Enveric Biosciences
1y agoENVBEnveric Biosciences Hires IP Powerhouse to Defend Its U.S. Patent with Claims Relevant to Bretisilocin, Recently Acquired by AbbVie in $1.2 Billion DealBusiness WireEB-003, Enveric's lead product candidate, is protected by a different patent family that includes an issued U.S. patent and pending U.S. and international patents, all of which are separate and distinct from the patent
1y agoENVBEnveric Biosciences to Explore Digital Asset Treasury OpportunitiesBusiness WireEnveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced that
1y agoENVBEnveric Biosciences Successfully Completes Key Manufacturing Milestones in Support of Planned IND and Clinical TrialsBusiness WireKey CMC achievements advance EB-003 on the path to first-in-human trials Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small
1y agoENVBEnveric Biosciences Announces Closing of Exercise of Warrants for $2.2 Million Gross ProceedsBusiness WireEnveric Biosciences, Inc. (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced
1y agoENVBEnveric Biosciences Receives FDA Response and Streamlines Plans for EB-003 IND SubmissionBusiness WireEnveric expects to file Investigational New Drug application for EB-003 in early 2026 Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic
1y agoENVBEnveric Biosciences to Present at H.C. Wainwright 27th Annual Global Investment ConferenceBusiness WireEnveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced that
1y agoENVBEnveric Biosciences Relocates Corporate Headquarters to Cambridge, MABusiness WireMove aligns with company's vision to leverage the Greater Boston biotech hub's scientific and financial ecosystem and advance EB-003 into first-in-human trial in 2026 Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or
1y agoENVBEnveric Biosciences Successfully Completes Pre-IND Dose Range Finding Studies for Lead Candidate EB-003, Targeting Neuropsychiatric IndicationsBusiness WireData establish maximum tolerated dose, supporting progression of lead neuroplastogen compound EB-003 toward IND-enabling studies and First-in-Human clinical trials Enveric Biosciences, Inc. (NASDAQ:ENVB) ("Enveric" or
1y agoENVBEnveric Biosciences Reports Second Quarter 2025 Financial and Corporate ResultsBusiness WireQ2 marked a critical inflection point in EB-003 development with mechanism confirmation, therapeutic opportunity expansion, IND-enabling progress, and continued strengthening of Enveric's differentiated neuroplastogen
1y agoENVBEnveric Biosciences Secures Second U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 SeriesBusiness WirePatent-protected methylone-inspired analogs support pipeline expansion into PTSD Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule
1y agoENVBEnveric Biosciences Lead Drug Candidate EB-003 Demonstrates Positive Effects in Preclinical Model of Post-Traumatic Stress Disorder (PTSD)Business WireEB-003 significantly decreased context-induced freezing behavior one-hour post-dose (p < 0.05) indicating a positive therapeutic effect in well-established translational rodent model for PTSD Enveric Biosciences
1y agoENVBEnveric Biosciences Announces Data that Broadens Scope of Clinical Indication Potential for Lead Candidate EB-003Business WireEB-003 revealed to also act as an agonist of the serotonin receptor 5-HT1B, a validated target of drugs approved to treat major depressive disorder and a variety of neurological conditions including Parkinson's disease,
1y agoENVBEnveric Biosciences Announces Participation in 2025 BIO International ConventionBusiness WireEnveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of psychiatric and
1y agoENVBEnveric Biosciences Receives Notice of Allowance for New Class of Low-Hallucinogenic Neuroplastogens Targeting Psychiatric DisordersBusiness WirePatent-protected aminated tryptamine derivatives strengthen Enveric's leadership in next-generation mental health treatments Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company
1y agoENVBEnveric Biosciences Announces Issuance of U.S. Patent Covering a Novel Family of Molecules Including Melatonin Receptor-Targeting CompoundsBusiness WireNew Intellectual Property Unlocks Potential for Sleep and CNS Therapeutics Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic